All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Darolutamide Plus ADT Gains EU Approval for mHSPC

July 21st 2025

Darolutamide receives EU approval with ADT for metastatic hormone-sensitive prostate cancer.

HARMONY Study Aims to Personalize PARP Inhibition in mHSPC Through Adaptive Design, Diverse Patient Enrollment

July 21st 2025

Qian (Janie) Qin, MD, discusses the importance of early molecular testing, evolving PARP inhibitor strategies, and the phase 2 HARMONY trial in mHSPC.

First-Line Osimertinib Plus Chemo Boosts OS in EGFR+ NSCLC

July 21st 2025

Osimertinib plus chemotherapy improved overall survival in the first-line treatment of advanced non–small cell lung cancer harboring EGFR mutations.

Real-World Analysis Highlights Potential Prognostic Impact of KRAS G12C Mutations in First-Line mCRC

July 21st 2025

Cathy Eng, MD, FACP, FASCO, discusses real-world data on KRAS G12C–mutated mCRC, highlighting its potential prognostic impact in the frontline setting.

KAT6 Inhibition Shows Path to Overcoming Resistance Mechanisms in ER+ Breast Cancer

July 21st 2025

PF-07248144 is a first-in-class selective inhibitor of KAT6A and KAT6B that has displayed the ability to suppress ER expression in a preclinical study.

Five Under 5: Top Oncology Videos for the Week of 7/13

July 20th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Long-Term Data Suggest Potential Functional Cure With MCL2/MCL3 Regimen in Younger Patients With Mantle Cell Lymphoma

July 20th 2025

Mats Jerkeman, MD, discusses long-term follow-up data of the Nordic MCL2 and MCL3 trials in younger patients with mantle cell lymphoma.

The OncFive: Top Oncology Articles for the Week of 7/13

July 19th 2025

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

Pooled Trial Data Highlight Potential of a Novel Biparatopic ADC in Heavily Pretreated HER2+ Breast Cancer

July 19th 2025

JSKN003 demonstrated tolerability and antitumor activity in heavily pretreated HER2-positive breast cancer.

Casdatifan Plus Cabozantinib Shows Meaningful Clinical Activity in Pretreated ccRCC

July 18th 2025

Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.

High Levels of CD163+ Tumor-Associated Macrophages Could Improve Outcomes With Nivolumab in Metastatic RCC

July 18th 2025

High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.

KIM-1 Represents a Potential Biomarker for Outcomes and Response in RCC

July 18th 2025

KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.

Pembrolizumab/Lenvatinib Combination Produces Durable Responses in Advanced Non–Clear Cell RCC

July 18th 2025

Findings from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Cancer-Fighting Herpes Virus Shown to be an Effective Treatment for Some Advanced Melanoma

July 18th 2025

A genetically engineered herpes simplex virus plus immunotherapy reduces or eliminates tumors in 1/3 of clinical trial patients, according to a new study.

FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL

July 18th 2025

The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia

July 18th 2025

Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.

FDA Grants Orphan Drug Designation to ICT01 for Acute Myeloid Leukemia

July 18th 2025

ICT01 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.

Belzutifan Prolongs Quality-Adjusted Time Without Symptoms or Toxicity in Advanced RCC

July 18th 2025

Treatment with belzutifan increased the time without progression or toxicity vs everolimus in patients with advanced RCC.

Metastasis-Directed Radiotherapy Yields Durable Disease Control Without Systemic Therapy in Oligometastatic RCC

July 18th 2025

Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.

ADC-, Bispecific Antibody–Based Therapies Help Build a New Treatment Paradigm in EGFR+ NSCLC

July 18th 2025

In an OncLive Peer Exchange, expert investigators convened to discuss the treatment landscape of early-stage NSCLC from a multidisciplinary perspective.